Andere Sprachen Opthea Limited

Aktien

Markt geschlossen - Australian S.E. Andere Börsenplätze 08:10:44 26.04.2024			% 5 Tage	% 1. Jan.
0,625 ^AUD	-7,41 %		-2,34 %	+9,65 %

03.04.	Opthea Limited kündigt Änderungen im Vorstand an	CI
29.02.	Opthea postet H1 FY24 Verlust pro Aktie von $0.1623; F&E-Aufwendungen springen	MT

Opthea to Present at the OIS Retina Innovation Summit at ARVO	25.04.
Opthea : to Present at the OIS Retina Innovation Summit at ARVO - Form 6-K	25.04.
Opthea Appoints John Han, PharmD, as VP Medical Affairs	09.04.
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference	05.04.
Opthea Appoints Sujal Shah to the Board of Directors	03.04.
Opthea Limited Announces Board Changes	03.04.
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024	19.03.
Opthea to Participate in the Leerink Partners Global Biopharma Conference	05.03.
Opthea Posts H1 FY24 Loss per Share of $0.1623; R&D Expenses Jump	29.02.
Opthea Reports Half-Year Financial Results and Business Updates	28.02.
Opthea Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28.02.
Opthea Appoints Chief Medical Advisor; Shares Decline 4%	20.02.
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor	20.02.
Opthea Appoints Arshad M. Khanani as Chief Medical Advisor	20.02.
Opthea Concludes Enrollment in Inaugural Wet AMD Drug Trial	15.02.
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept	14.02.
Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept	14.02.
Opthea Makes Management Appointments As Part of Next Stage Drug Trial; Shares Up 13%	02.02.
Opthea Strengthens Team with Key Clinical and Regulatory Hires	01.02.
Opthea Strengthens Team with Key Clinical and Regulatory Hires	01.02.

Keine Ergebnisse zu dieser Suche